Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age‐related macular degeneration

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Acta ophthalmologica

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1755-3768.2008.01312.xPMID 18937801
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravitreal bevacizumab for neovascular age-related macular degeneration

  2009cited by this paper
• Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

  2008cited by this paper
• Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography

  2008cited by this paper
• Complications in patients after intravitreal injection of bevacizumab

  2008cited by this paper
• Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2007cited by this paper
• RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2007influential reference
• Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study

  2007cited by this paper
• Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.

  2007influential reference
• Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

  2007influential reference
• Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration.

  2007cited by this paper
• Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration

  2006cited by this paper
• ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)

  2006cited by this paper
• TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)

  2006cited by this paper
• Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.

  2006influential reference
• INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

  2006influential reference
• Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.

  2006influential reference
• Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.

  2006influential reference
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006influential reference
• Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.

  2006cited by this paper
• Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.

  2006cited by this paper
• [Intravitreal bevacizumab for neovascular age-related macular degeneration].

  2006cited by this paper
• Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

  2005influential reference
• Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

  2005influential reference
• Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer

  2005cited by this paper
• Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

  2004influential reference
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004influential reference
• Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment.

  2004cited by this paper
• POTENTIAL PUBLIC HEALTH IMPACT OF AGE-RELATED EYE DISEASE STUDY RESULTS: AREDS REPORT NO. 11

  2004cited by this paper
• New agents in colon cancer.

  2003influential reference
• Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.

  2003cited by this paper
• Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis

  1999influential reference
• Role of vascular endothelial growth factor in the regulation of angiogenesis.

  1999cited by this paper
• Increased expression of angiogenic growth factors in age-related maculopathy

  1997influential reference
• Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.

  1996cited by this paper
• Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.

  1996influential reference
• Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

  1994influential reference

• Therapeutic measures for sulfur mustard-induced ocular injury.

  2021cites this paper
• Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization

  2020cites this paper
• Comparing the effect of Avastin alone with intravitreal tissue plasminogen activator plus Avastin on hemorrhagic choroidal neovascularization in patients with neovascular age related macular degeneration

  2019cites this paper
• Regulation of inflammation and angiogenesis in the cornea

  2018cites this paper
• Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

  2017cites this paper
• Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.

  2016cites this paper
• The Effects of the Frequency of the Initial Treatment with Intravitreal Bevacizumab on Macular Volume and Visual Acuity

  2015cites this paper
• Predictors of visual and anatomical outcomes for neovascular age-related macular degeneration treated with bevacizumab.

  2015cites this paper
• Drug Information Rounds

  2015cites this paper
• The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review

  2014influential citation
• The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema

  2014cites this paper
• Subconjunctival Bevacizumab for Primary Pterygium Excision; a Randomized Clinical Trial

  2014cites this paper
• Trophic factors in the pathogenesis and therapy for retinal degenerative diseases.

  2014cites this paper
• Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration

  2013cites this paper
• A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

  2013cites this paper
• Corneal neovascularization: an anti-VEGF therapy review.

  2012cites this paper
• Possibilities of infection and increase of intraocular pressure after intravitreal application of bevacizumab in treatment of exudative form of AMD.

  2012cites this paper
• Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy.

  2011cites this paper
• Reconstructing vision - undone Science and Anti-VEGF treatment of wet age-related macular degeneration

  2011cites this paper
• A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS

  2011cites this paper
• Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age‐related macular degeneration

  2011cites this paper
• Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration in Clinical Practice

  2011cites this paper
• Efficacy of 12‐month treatment of neovascular age‐related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections

  2011cites this paper
• Prevention of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Its Topical Form in Experimental Rats

  2011cites this paper
• Bilateral Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration: Effect of Baseline Visual Acuity

  2011cites this paper
• Antiangiogénicos na Degenerescência Macular Relacionada com a Idade: A Medicina Baseada na Evidência e a Utilização Off-label

  2011influential citation
• Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature

  2010cites this paper
• Bevacizumab for the treatment of neovascular age related macular degeneration

  2010cites this paper
• Aggressive wet age-related macular degeneration

  2010cites this paper
• Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe

  2009cites this paper
• A PROSPECTIVE STUDY OF BLOOD PRESSURE AND INTRAOCULAR PRESSURE CHANGES IN HYPERTENSIVE AND NONHYPERTENSIVE PATIENTS AFTER INTRAVITREAL BEVACIZUMAB INJECTION

  2009cites this paper
• Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

  2009cites this paper
• VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Randomized, Controlled Trial

  2009cites this paper